{"filings":[{"id":2198516,"accession_number":"0001104659-26-094391","cik":842023,"company_name":"BIO-TECHNE Corp","ticker":"TECH","form_type":"8-K","filed_at":"2026-08-12T10:30:30+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Bio-Techne Q4 revenue $321M, adjusted EPS $0.52; dividend $0.08; Merck deal on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $321.2M (+1% reported, +3% organic); FY26 flat at $1.2B","Q4 GAAP EPS $0.35 vs $(0.11) prior year; adjusted EPS $0.52 vs $0.53","FY26 GAAP EPS $1.16 vs $0.46; adjusted EPS $1.93 vs $1.92","Quarterly dividend $0.08/share, payable Sept 4, 2026, record Aug 24","Merck KGaA acquisition at $73/share cash, ~$11.3B EV, on track"],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7529391672.209507,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1285442,"accession_number":"0001999371-26-013527","cik":842023,"company_name":"BIO-TECHNE Corp","ticker":"TECH","form_type":"8-K","filed_at":"2026-06-25T22:49:24+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"Bio-Techne to be acquired by Merck KGaA for $73.00 per share in all-cash deal","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merck KGaA to acquire Bio-Techne (TECH) for $73.00 per share in cash.","Termination fees: Company pays $230.5M for superior proposal; Parent pays $576.1M for antitrust failure.","Retention bonuses: CEO Kelderman $2.12M, CFO Hippel $1.54M, plus Geist $1.16M, Bohnen $0.97M, Crouse $0.91M.","Closing requires shareholder approval, HSR and antitrust clearances; outside date Mar 25, 2027, extendable.","Board unanimously recommends the merger; subject to no-shop and fiduciary-out provisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":7529391672.209507,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1259276,"accession_number":"0001999371-26-013429","cik":842023,"company_name":"BIO-TECHNE Corp","ticker":"TECH","form_type":"8-K","filed_at":"2026-06-25T12:21:30+00:00","items":["7.01","5.02","9.01"],"status":"ready","headline":"Merck KGaA to acquire Bio-Techne for $73/share in $11.3B deal","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Purchase price $73/share in cash; enterprise value $11.3B (EUR 9.9B); 36% premium to 1-month VWAP.","Expected to close by late 2026 / early 2027, subject to shareholder and regulatory approvals.","Annual cost synergies of ~EUR 140M expected fully realized by year 3 post-close.","Bio-Techne FY2025 net sales >$1.2B; ~3,000 employees; to operate as part of Merck KGaA Life Science.","Transaction approved by Bio-Techne Board and Merck corporate bodies; debt-funded with investment-grade credit maintained."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":7529391672.209507,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99156,"accession_number":"0001104659-26-055887","cik":842023,"company_name":"BIO-TECHNE Corp","ticker":"TECH","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Bio-Techne Q3 revenue down 2% to $311.4M, adj EPS $0.53; declares $0.08 dividend","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $311.4M, down 2% reported and organic; GAAP EPS $0.32 (up from $0.14), adjusted EPS $0.53 (down from $0.56).","Large pharma grew double-digits for sixth consecutive quarter; U.S. academic market stabilized with low-single-digit growth; emerging biotech spending still lagging.","Protein Sciences segment sales $226.2M (down 1% reported); segment margin 44.2% vs 45.6%.","Diagnostics & Spatial Biology segment sales $85.6M (down 4% reported, up 3% organic); segment margin improved to 12.1% from 9.4%.","Declared quarterly dividend $0.08 per share, payable May 29, 2026 to shareholders of record May 18, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":0.81,"consensus_revenue_estimate":null,"consensus_revenue_actual":893847000.0,"consensus_period":"2026-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7529391672.209507,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115005,"accession_number":"0001104659-26-013412","cik":842023,"company_name":"BIO-TECHNE Corp","ticker":"TECH","form_type":"8-K","filed_at":"2026-02-11T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Bio-Techne appoints Steve Crouse as DSS President effective March 1; McManus transitions out","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Matt McManus will transition from President, Diagnostics and Spatial Biology Segment effective March 1, 2026, and remain to support transition.","Steve Crouse, previously SVP of Analytical Solutions, named successor; he joined in 2022 from Thermo Fisher Scientific.","Crouse's employment agreement includes base salary of $505,000, target cash bonus of 75% of base, and equity awards valued at ~$170,000 one-time and ~$1.2M annual target.","McManus's termination approved without cause; he will receive severance per employment agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":7529391672.209507,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115004,"accession_number":"0001104659-26-009994","cik":842023,"company_name":"BIO-TECHNE Corp","ticker":"TECH","form_type":"8-K","filed_at":"2026-02-04T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Bio-Techne Q2 revenue flat at $295.9M; adjusted EPS rises to $0.46 from $0.42","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP EPS of $0.24 vs $0.22; adjusted EPS of $0.46 vs $0.42, both year-over-year increases.","Protein Sciences segment revenue +2% to $215.1M; operating margin fell to 39.3% from 41.2%.","Diagnostics & Spatial Biology segment revenue -4% to $81.2M; organic growth +3% with margin up to 10.4%.","Board declares $0.08/share quarterly dividend, payable Feb 27, 2026 to holders of record Feb 16, 2026.","China/APAC region drove growth for third consecutive quarter; large pharma end-market grew double digits."],"consensus_eps_estimate":null,"consensus_eps_actual":0.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":582432000.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7529391672.209507,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131389,"accession_number":"0001104659-25-106631","cik":842023,"company_name":"BIO-TECHNE Corp","ticker":"TECH","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","5.07","8.01","9.01"],"status":"ready","headline":"Bio-Techne Q1 FY2026 revenue down 1% to $286.6M; adjusted EPS flat $0.42; declares $0.08 dividend","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $286.6M (-1% YoY); GAAP EPS $0.24 (up from $0.21); adjusted EPS $0.42 (flat).","Protein Sciences segment rev $202.2M (-1% YoY); op margin 38.4% vs 39.4%.","Diagnostics & Spatial Biology rev $79.5M (-4%), organic +3%; op margin 11.2% vs 5.1% (benefited from Exosome divestiture).","Completed Exosome Diagnostics divestiture; CEO notes biotech funding headwinds but stability in US academic.","Declares quarterly dividend $0.08/share, payable Nov 28 to holders of record Nov 17."],"consensus_eps_estimate":null,"consensus_eps_actual":0.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":286555000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7529391672.209507,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147982,"accession_number":"0001558370-25-010393","cik":842023,"company_name":"BIO-TECHNE Corp","ticker":"TECH","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Bio-Techne Q4 GAAP EPS -$0.11, adjusted EPS $0.53; organic revenue +3%; announces Exosome divestiture","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP EPS loss of $0.11 vs $0.25 profit a year ago; adjusted EPS $0.53 vs $0.49.","Q4 organic revenue up 3% (reported 4%) to $317.0M; full year organic +5% to $1.2B.","Protein Sciences segment organic growth 4% (reported 6%) in Q4.","Announced divestiture of Exosome Diagnostics business including ExoDx Prostate test.","Board declared $0.08/share quarterly dividend, payable Aug 29, record Aug 18."],"consensus_eps_estimate":null,"consensus_eps_actual":0.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":1219635000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":7529391672.209507,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166702,"accession_number":"0001558370-25-006594","cik":842023,"company_name":"BIO-TECHNE Corp","ticker":"TECH","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Bio-Techne Q3 revenue $316.2M (+6% organic), adj EPS $0.56, declares $0.08 dividend and $500M buyback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 organic revenue +6% to $316.2M; GAAP EPS $0.14 vs $0.31 YoY; adjusted EPS $0.56 vs $0.48 YoY.","Protein Sciences segment organic growth 7% (reported 6%) on improved pharma demand and commercial execution.","Adjusted operating margin improved to 34.9% from 33.0% YoY; reported margin 12.2% (incl. charges).","Declared quarterly dividend $0.08/share, payable May 30, 2025 to holders of record May 19, 2025.","Board approved new $500M share repurchase program, effective May 8, 2025, replacing prior program."],"consensus_eps_estimate":0.4287,"consensus_eps_actual":0.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":902671000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7529391672.209507,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166701,"accession_number":"0001558370-25-006512","cik":842023,"company_name":"BIO-TECHNE Corp","ticker":"TECH","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Bio-Techne authorizes $500M share repurchase program, replacing prior 2022 authorization","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized up to $500M in common stock repurchases on April 30, 2025.","Replaces the prior $500M program approved February 2, 2022; no expiration date set.","Repurchases may be made in open market, private transactions, or block trades.","Management retains discretion based on market conditions, stock price, and capital needs.","Program intends to offset dilution from stock option exercises among other purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7529391672.209507,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184122,"accession_number":"0001558370-25-002177","cik":842023,"company_name":"BIO-TECHNE Corp","ticker":"TECH","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Bio-Techne ordered to pay former CEO $35.98M over option expiration error","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Arbitrator awarded former CEO Charles Kummeth $35.978M for options lost due to administrative error.","Options expired August 9, 2024 per award agreements; company's platform erroneously showed October 26, 2024.","Interest of $980,000 and legal fees/costs of $234,000 also awarded to Kummeth.","Award calculated using average closing price of TECH common stock over 30 days before actual expiration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7529391672.209507,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184121,"accession_number":"0001558370-25-000639","cik":842023,"company_name":"BIO-TECHNE Corp","ticker":"TECH","form_type":"8-K","filed_at":"2025-02-05T23:59:59+00:00","items":["2.02","5.02","8.01","9.01"],"status":"ready","headline":"Bio-Techne Q2 organic revenue +9% to $297M, adjusted EPS $0.42; declares $0.08 dividend","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 organic revenue up 9% to $297.0M; GAAP EPS $0.22 vs $0.17, adjusted EPS $0.42 vs $0.40.","Protein Sciences segment grew 8% organic; Diagnostics & Spatial Biology grew 12% organic.","Declared $0.08 per share quarterly dividend, payable Feb 28, 2025 to holders of record Feb 17, 2025.","Dr. Amy Herr appointed independent director effective Feb 1, 2025; serves on Science & Technology Committee."],"consensus_eps_estimate":0.5089,"consensus_eps_actual":0.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":586489000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7529391672.209507,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200713,"accession_number":"0001558370-24-014442","cik":842023,"company_name":"BIO-TECHNE Corp","ticker":"TECH","form_type":"8-K","filed_at":"2024-11-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Bio-Techne grants CFO James Hippel 34,634 RSUs to correct forfeited options","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Grant date: October 30, 2024; vesting in three equal annual installments.","Award under 2020 Equity Incentive Plan; retention purpose cited.","Grant compensates for stock options forfeited due to administrative error in expiration date recording.","Shares: 34,634; subject to continued service and plan terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":7529391672.209507,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200712,"accession_number":"0001558370-24-013879","cik":842023,"company_name":"BIO-TECHNE Corp","ticker":"TECH","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["2.02","5.07","8.01","9.01"],"status":"ready","headline":"Bio-Techne Q1 revenue $289.5M (organic +4%), adj EPS $0.42; declares $0.08 dividend","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $289.5M, up 5% reported (4% organic); GAAP EPS $0.21 vs $0.31; adjusted EPS $0.42 vs $0.41.","Diagnostics & Spatial Biology segment organic growth 14%; cell and gene therapy workflow solutions strong.","Dividend of $0.08 per share declared, payable Nov 22 to holders of record Nov 11.","Annual meeting: board set at 9, all director nominees elected, say-on-pay approved, KPMG ratified."],"consensus_eps_estimate":null,"consensus_eps_actual":0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":289458000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7529391672.209507,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216733,"accession_number":"0001558370-24-011193","cik":842023,"company_name":"BIO-TECHNE Corp","ticker":"TECH","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Bio-Techne Q4 adjusted EPS $0.49 vs $0.55 YoY; revenue $306.1M (+2%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 organic revenue up 1% to $306.1M; FY2024 organic revenue up 1% to $1.2B.","GAAP EPS $0.25 vs $0.47; adjusted EPS $0.49 vs $0.55.","Diagnostics & Genomics segment grew 9% organically in Q4.","FY2024 operating cash flow $299M, up 18% YoY.","Board declared $0.08 quarterly dividend payable Aug 30, record Aug 19."],"consensus_eps_estimate":null,"consensus_eps_actual":1.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":1159060000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7529391672.209507,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236413,"accession_number":"0001558370-24-006319","cik":842023,"company_name":"BIO-TECHNE Corp","ticker":"TECH","form_type":"8-K","filed_at":"2024-05-01T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Bio-Techne Q3 FY2024: Revenue $303.4M (+2% organic); GAAP EPS $0.31 vs $0.43; declares $0.08 dividend","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $303.4M (organic +2%, reported +3%); GAAP EPS $0.31 vs $0.43; adjusted EPS $0.48 vs $0.53.","Diagnostics & Genomics segment organic growth 10% (reported 16%); record GMP reagent sales in cell/gene therapy.","Cash from operations $223.5M, up 31% YoY.","Quarterly dividend of $0.08 per share, payable May 24, 2024; record date May 13, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":0.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":852961000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7529391672.209507,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236412,"accession_number":"0001558370-24-006279","cik":842023,"company_name":"BIO-TECHNE Corp","ticker":"TECH","form_type":"8-K","filed_at":"2024-04-30T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Bio-Techne appoints Dr. Judith Klimovsky to board, expands to 11 directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Klimovsky appointed independent director effective April 24, 2024; board temporarily expanded to 11 members (10 independent).","She will serve on the Science & Technology Committee.","Dr. Klimovsky is EVP & Chief Development Officer at Genmab; previously held senior roles at Novartis Oncology and Bristol-Myers Squibb.","Board also approved a one-year waiver of mandatory retirement policy for Dr. Roeland Nusse."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":7529391672.209507,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254075,"accession_number":"0001558370-24-000683","cik":842023,"company_name":"BIO-TECHNE Corp","ticker":"TECH","form_type":"8-K","filed_at":"2024-02-01T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Bio-Techne Q2 organic revenue down 2% to $272.6M; GAAP EPS $0.17 vs $0.31 YoY; declares $0.08 dividend","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 organic revenue declined 2% to $272.6M; reported revenue flat vs prior year.","GAAP EPS $0.17 vs $0.31 YoY; adjusted EPS $0.40 vs $0.47.","Cash flow from operations $142.5M, up 18% YoY.","Board declared $0.08 per share quarterly dividend, payable Feb 26, 2024.","Dr. Matthew F. McManus appointed President of Diagnostics and Genomics segment."],"consensus_eps_estimate":null,"consensus_eps_actual":0.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":549533000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7529391672.209507,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254074,"accession_number":"0001558370-24-000125","cik":842023,"company_name":"BIO-TECHNE Corp","ticker":"TECH","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Bio-Techne appoints Matthew McManus as President DGS; Kim Kelderman to become CEO Feb 1, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Matthew McManus appointed President – Diagnostics and Genomics Segment, effective Jan 8, 2024.","McManus receives $550K base salary, 90% target cash incentive, $950K RSU grant, and other equity awards.","McManus succeeds Kim Kelderman, who will become Bio-Techne CEO effective Feb 1, 2024.","Employment agreement has three-year initial term; severance equal to one year base salary plus prorated incentive.","McManus previously led Bio-Techne's Molecular Diagnostics Division after Asuragen acquisition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7529391672.209507,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271540,"accession_number":"0001558370-23-017051","cik":842023,"company_name":"BIO-TECHNE Corp","ticker":"TECH","form_type":"8-K","filed_at":"2023-10-31T23:59:59+00:00","items":["2.02","5.07","8.01","9.01"],"status":"ready","headline":"Bio-Techne Q1 GAAP EPS $0.31 (down 44% YoY); CEO Kelderman appointed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS $0.31 vs $0.55 prior year; adjusted EPS $0.41 vs $0.45.","Revenue $276.9M, organic growth +2% (+3% reported).","ExoDx test volume +49%; GMP proteins revenue +39%; ProteinSimple +9% (ex-China +18%).","Cash from ops $59.4M, +6% YoY.","Declared quarterly dividend $0.08/share payable Nov 24; CEO Kim Kelderman effective Feb 1, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":0.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":276935000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7529391672.209507,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271539,"accession_number":"0001558370-23-016529","cik":842023,"company_name":"BIO-TECHNE Corp","ticker":"TECH","form_type":"8-K","filed_at":"2023-10-19T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Bio-Techne CEO Chuck Kummeth to retire; Kim Kelderman named successor effective Feb 1, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kelderman becomes COO Nov 1, 2023, then CEO and board member Feb 1, 2024; Kummeth to serve as Senior Advisor until July 1, 2024.","CEO salary set at $900,000 base (COO $750,000), target bonus 110% (COO 100%); equity grants valued at $6.2M total.","Kelderman has led Diagnostics & Genomics since 2018; previously executive at Thermo Fisher and BD.","Retention RSUs awarded to candidates Geist (~$1.05M) and Hippel (~$1.39M) vesting over two years.","Kummeth tenure: revenue grew from $311M to $1.1B, 19 acquisitions, headcount from 800 to 3,200."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7529391672.209507,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288417,"accession_number":"0001558370-23-013727","cik":842023,"company_name":"BIO-TECHNE Corp","ticker":"TECH","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Bio-Techne Q4 revenue up 5% to $301.3M; GAAP EPS $0.47 vs $0.38, adjusted EPS $0.55 vs $0.51","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year organic revenue grew 5% to $1.1B; GAAP EPS $1.76, adjusted EPS $1.99.","Diagnostics & Genomics segment organic growth 10% in Q4; full-year 8%.","ExoDx prostate test revenue surged 68% in Q4; GMP proteins up 58%.","Acquired Lunaphore (COMET spatial biology platform) – no deal value disclosed.","Quarterly dividend declared $0.08/share, payable Sept 1, record Aug 18."],"consensus_eps_estimate":null,"consensus_eps_actual":1.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":1136702000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7529391672.209507,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":308907,"accession_number":"0001558370-23-007739","cik":842023,"company_name":"BIO-TECHNE Corp","ticker":"TECH","form_type":"8-K","filed_at":"2023-05-03T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Bio-Techne reports Q3 fiscal 2023 results and declares cash dividend; specific figures not available","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Press release for quarter ended March 31, 2023 issued May 3, 2023.","Dividend announcement made same day with no per-share amount disclosed in filing.","No financial figures, guidance, or YoY comparisons provided in the 8-K body."],"consensus_eps_estimate":null,"consensus_eps_actual":1.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":835382000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":7529391672.209507,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":308906,"accession_number":"0001558370-23-005339","cik":842023,"company_name":"BIO-TECHNE Corp","ticker":"TECH","form_type":"8-K","filed_at":"2023-04-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bio-Techne completes $257M investment for 20% stake in Wilson Wolf; future buyout potential $1B","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["$257M investment gives Bio-Techne 20% ownership of Wilson Wolf Manufacturing.","Investment triggered by Wilson Wolf achieving $55M trailing twelve-month EBITDA.","Bio-Techne has right to acquire remaining 80% for $1B if Wilson Wolf reaches $226M revenue or $136M EBITDA.","If milestone not met by Dec 31, 2027, acquisition price ~4.4x trailing twelve-month revenue.","Wilson Wolf develops G-Rex cell production technology for cell and gene therapy; used by over 800 CGT market participants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":7529391672.209507,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":327680,"accession_number":"0001558370-23-002475","cik":842023,"company_name":"BIO-TECHNE Corp","ticker":"TECH","form_type":"8-K","filed_at":"2023-03-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bio-Techne invests $257M for 20% of Wilson Wolf; future buyout up to $1B","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Wilson Wolf met trailing 12-month EBITDA target of $55M, triggering Bio-Techne's option.","Bio-Techne will pay $257M for a 20% ownership stake; close expected end of March 2023.","Remaining 80% can be acquired for $1B if Wilson Wolf hits $226M revenue or $136M EBITDA.","If milestone not met by Dec 31, 2027, Bio-Techne can buy for ~4.4x trailing revenue.","Wilson Wolf's G-Rex cell production tech is used by over 800 cell and gene therapy entities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7529391672.209507,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":327679,"accession_number":"0001558370-23-000758","cik":842023,"company_name":"BIO-TECHNE Corp","ticker":"TECH","form_type":"8-K","filed_at":"2023-02-02T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Bio-Techne Q2 FY2023: organic revenue up 4% to $271.6M; GAAP EPS $0.31 vs $0.49 YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Organic revenue grew 4% to $271.6M; reported revenue up 1%.","GAAP EPS $0.31, down from $0.49; adjusted EPS $0.47, flat YoY (FX headwind $0.02).","ExoDx Prostate test revenue more than doubled YoY; fourth consecutive record quarter.","Board declared $0.08/share quarterly dividend, payable Feb 27 to holders of record Feb 13.","Record GMP protein sales and launch of RNAscope Plus and MauriceFlex instrument."],"consensus_eps_estimate":null,"consensus_eps_actual":0.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":541236000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7529391672.209507,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":327678,"accession_number":"0001558370-23-000715","cik":842023,"company_name":"BIO-TECHNE Corp","ticker":"TECH","form_type":"8-K","filed_at":"2023-01-31T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Bio-Techne appoints Shane Bohnen as SVP, General Counsel; Brenda Furlow retires March 3, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Shane Bohnen, previously Associate General Counsel since 2019, becomes Senior VP, General Counsel effective March 3, 2023.","Brenda Furlow, EVP & General Counsel for nine years, retires March 3, 2023; will remain as consultant for special projects.","Bohnen's compensation: $331,500 base salary, 50% target cash bonus, one-time $500,000 RSU grant vesting over three years.","Bohnen has over 20 years legal experience including private practice and in-house at Smiths Medical and Resideo."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":7529391672.209507,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":345381,"accession_number":"0001558370-22-015710","cik":842023,"company_name":"BIO-TECHNE Corp","ticker":"TECH","form_type":"8-K","filed_at":"2022-11-01T23:59:59+00:00","items":["2.02","5.03","5.07","8.01","9.01"],"status":"ready","headline":"Bio-Techne Q1 FY2023 revenue up 7% organic, GAAP EPS $2.21, declares 4-for-1 stock split","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $269.7M, up 5% reported / 7% organic YoY.","GAAP diluted EPS $2.21 (vs $1.69); adjusted diluted EPS $1.78 (vs $1.83, FX impact $0.12).","Diagnostics & Genomics segment organic growth of 17%; ExoDx Prostate test revenue +100% YoY.","Operating cash flow $56.1M, up 16% YoY.","Board declared $0.32/share quarterly cash dividend (payable Nov 28) and 4-for-1 stock split (distributed Nov 29, trading split-adjusted Nov 30)."],"consensus_eps_estimate":null,"consensus_eps_actual":2.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":269655000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7529391672.209507,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":361833,"accession_number":"0001558370-22-014215","cik":842023,"company_name":"BIO-TECHNE Corp","ticker":"TECH","form_type":"8-K","filed_at":"2022-09-07T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Bio-Techne enters $1B revolving credit facility; draws $350M to repay prior debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New $1B revolving credit facility, expandable by $400M, matures August 31, 2027.","Borrowed $350M at closing to repay existing term and revolving loans under prior credit agreement.","Facility bears variable interest based on total leverage ratio; includes sustainability-linked option.","Maintains minimum interest coverage ratio of 3.00x and max total debt-to-EBITDA of 3.50x (4.00x post-qualified acquisition)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":7529391672.209507,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":361832,"accession_number":"0001558370-22-012336","cik":842023,"company_name":"BIO-TECHNE Corp","ticker":"TECH","form_type":"8-K","filed_at":"2022-08-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Bio-Techne CEO Chuck Kummeth plans to retire by June 30, 2024; board begins successor search","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Revenue grew from $311M in FY2013 to $1.1B in FY2022 (CAGR >15%); employees grew from 800 to 3,000+.","Kummeth to receive 150k performance-vesting stock options for FY2023 and another 150k for FY2024, plus a $5M RSU award vesting over three years.","No base salary increase; bonus target remains at 160% of salary. Kummeth will stay on as CEO during the two-year transition.","Board evaluating internal and external CEO candidates; Kummeth is expected to remain on the board after retirement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7529391672.209507,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":361831,"accession_number":"0001558370-22-012028","cik":842023,"company_name":"BIO-TECHNE Corp","ticker":"TECH","form_type":"8-K","filed_at":"2022-08-04T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Bio-Techne announces Q4 FY2022 earnings and quarterly cash dividend","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Results for fiscal fourth quarter ended June 30, 2022; specific figures not available in provided text.","Cash dividend declared; amount, record date, and payable date not specified in filing text.","No other material events reported in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":6.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":1105599000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":7529391672.209507,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":381260,"accession_number":"0001558370-22-006932","cik":842023,"company_name":"BIO-TECHNE Corp","ticker":"TECH","form_type":"8-K","filed_at":"2022-05-04T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Bio-Techne Q3 FY2022 revenue $290.4M (+17% organic), record adj. EPS $2.14","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 organic revenue +17% to $290.4M (reported +19%); YTD organic +18% to $817.4M.","Record adjusted EPS $2.14 (GAAP EPS $1.48) vs $1.80 prior year.","Protein Sciences organic +16%; Diagnostics & Genomics organic +19%.","Declared quarterly dividend $0.32/share, payable May 27 to holders of record May 16.","Announced exclusive agreement with Thermo Fisher to commercialize ExoTRU kidney transplant test."],"consensus_eps_estimate":null,"consensus_eps_actual":5.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":817371000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7529391672.209507,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":381259,"accession_number":"0001558370-22-006121","cik":842023,"company_name":"BIO-TECHNE Corp","ticker":"TECH","form_type":"8-K","filed_at":"2022-04-27T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Bio-Techne adopts Fourth Amended and Restated Bylaws with new shareholder meeting procedures","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Uncontested director elections changed to majority of votes cast, consistent with amended articles.","Shareholder proposal and nomination notice window moved to 90-120 days before anniversary of prior annual meeting.","Shareholders soliciting support for director nominees must represent intent to seek 67% voting power and provide evidence.","Lead Director position established; Chairman and Lead Director are non-officer roles.","Board may hold special meetings on less than 24 hours' notice if deemed necessary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":7529391672.209507,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":399267,"accession_number":"0001437749-22-002038","cik":842023,"company_name":"BIO-TECHNE Corp","ticker":"TECH","form_type":"8-K","filed_at":"2022-02-01T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Bio-Techne Q2 FY2022: GAAP EPS $1.94, adj EPS $1.88; rev $269.3M; $0.32 dividend, $400M buyback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Organic revenue +17% to $269.3M; Protein Sciences organic growth 19% with ProteinSimple up 27% and GMP Proteins >180%.","GAAP EPS $1.94 vs $1.15 YoY; record adjusted EPS $1.88 vs $1.62 YoY.","Adjusted operating income $102.8M, margin 38.3%; up 18% YoY.","Board declared $0.32 quarterly dividend, payable Feb 25, 2022 to holders of record Feb 11, 2022.","New $400M share repurchase program approved, replacing prior program, effective Feb 2, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":3.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":526995000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7529391672.209507,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":418252,"accession_number":"0001437749-21-029110","cik":842023,"company_name":"BIO-TECHNE Corp","ticker":"TECH","form_type":"8-K","filed_at":"2021-12-22T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Bio-Techne appoints Will Geist President, Protein Sciences Segment, succeeding retiring Dave Eansor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Geist, former COO of Quanterix and former VP/GM at Thermo Fisher, appointed effective Jan 3, 2022.","He succeeds N. David Eansor, who will retire and assist transition through Feb 2022.","Base salary $500,000; target cash bonus 85%; annual equity grants ~$1.8M; one-time RSU grant $1M.","Geist has over 20 years senior life science tools experience; CEO highlighted his experience running >$1B revenue businesses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7529391672.209507,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":418251,"accession_number":"0001437749-21-024807","cik":842023,"company_name":"BIO-TECHNE Corp","ticker":"TECH","form_type":"8-K","filed_at":"2021-11-02T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Bio-Techne Q1 FY2022 revenue $257.7M, organic growth 21%; adjusted EPS $1.83 vs $1.43","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 FY2022 revenue $257.7M, organic growth 21% (reported 26%).","GAAP EPS $1.69, adjusted EPS $1.83 vs $1.43 prior year.","Protein Sciences organic growth 26% (third consecutive quarter >20%).","China revenue grew over 50% organic; North America and Europe at least 20%.","Board declared $0.32 per share dividend payable Nov 26, 2021 to holders of record Nov 12."],"consensus_eps_estimate":null,"consensus_eps_actual":1.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":257719000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7529391672.209507,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":418250,"accession_number":"0001437749-21-024664","cik":842023,"company_name":"BIO-TECHNE Corp","ticker":"TECH","form_type":"8-K","filed_at":"2021-10-29T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Bio-Techne annual meeting: say-on-pay passes with 55.3% support; all directors elected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Say-on-pay vote: 18,728,833 for, 15,113,930 against (55.3% approval excluding broker non-votes).","Board set at nine directors; all nine nominees elected, including Charles Kummeth and Robert Baumgartner.","Ratification of KPMG as auditor approved with 34,401,952 for, 689,962 against.","Quorum of 35,099,608 shares (89.5% of outstanding) present at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.15,"market_cap_usd":7529391672.209507,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":435820,"accession_number":"0001437749-21-018609","cik":842023,"company_name":"BIO-TECHNE Corp","ticker":"TECH","form_type":"8-K","filed_at":"2021-08-05T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Bio-Techne Q4 FY2021 revenue up 47% to $259M; adjusted EPS $1.87 vs $1.00 YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 organic revenue rose 39% to $259.0M; GAAP EPS $0.37, adjusted EPS $1.87 (vs $1.00 prior year).","Full-year revenue $931.0M, adjusted EPS $6.75, record operating cash flow $352M.","Protein Sciences organic +46%, Diagnostics & Genomics +22%; adj. operating margin 38.5% vs 31.1%.","Board declares $0.32/share quarterly dividend, payable Aug 27, 2021 to holders of record Aug 16, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":3.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":931032000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7529391672.209507,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}